View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events4SC 배당 및 자사주 매입배당 기준 점검 0/64SC 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-366.8%자사주 매입 수익률총 주주 수익률-366.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates분석 기사 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.분석 기사 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024공시 • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023분석 기사 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).공시 • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.공시 • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023공시 • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 VSC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: VSC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장4SC 배당 수익률 vs 시장VSC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VSC)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (VSC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VSC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VSC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VSC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: VSC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/18 20:25종가2025/12/16 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스4SC AG는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Linda PomeroyEdison Investment ResearchMarcus WieprechtStifel, Equities Research
분석 기사 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
공시 • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).
공시 • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
공시 • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
공시 • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023
분석 기사 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...
Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).
공시 • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.
공시 • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023
공시 • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023
Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.